Nuformix PLC (NFXN)

London
0.5000
+0.0100(+2.00%)
  • Volume:
    1,017,589
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    0.5100 - 0.5100

NFXN Overview

Prev. Close
0.5
Day's Range
0.51-0.51
Revenue
50K
Open
0.51
52 wk Range
0.285-1.9325
EPS
-0.002
Volume
1,017,589
Market Cap
3.79M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
4,976,945
P/E Ratio
-3.24
Beta
0.668
1-Year Change
-67.74%
Shares Outstanding
709,309,368
Next Earnings Date
12 Dec 2022
What is your sentiment on Nuformix?
or
Market is currently closed. Voting is open during market hours.

Nuformix PLC Company Profile

Nuformix PLC Company Profile

Employees
4

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellSellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • I think this is one of those shares that fell to its bottom, made progress and now has everyone's interest again. I think it is set to bounce to 1.0 fairly easy then onward and upwards depending on the company. Last raise was December and the presentation is on 22 September so Id expect good investment from there on in . RNS Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that both of the abstracts submitted for presentation at the European Respiratory Society ("ERS") International Congress 2022 in Barcelona on September 4-6, on its lead asset NXP002, have been peer-reviewed and accepted for presentation. NXP002 is a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF"). Commenting, Dr Julian Gilbert, Non-executive Director of Nuformix, said: "We believe NXP002 offers tremendous potential as a novel inhaled treatment for IPF and potentially other fibrosing interstitial lung diseases ("ILDs"). The Company is progressing a pre-clinical programme to demonstrate how its proprietary new form of tranilast can down regulate fibrosis and inflammation following inhalation, whilst avoiding severe side effects, which are key issues in the treatment of IPF and other ILDs. We are therefore delighted that the abstracts describing our initial work have been accepted following peer review. Now, sounds better than good!!!
    0
    • 100% Bullish Here
      2
      • Strong buy...so much positive news. due q1
        5
        • What news? Never came...
          1
      • Nice to see a positive rns onwards and upwards
        2
        • much more to come. Hold for next waves. sales news and other milestones such as NX0002
          0
          • This could seriously do multiples of current SP.
            2